Clinically, PLK1 is established as a prognostic marker and a therapeutic target for the majority of solid, blood, and metastatic cancers, including gastric cancer 19, NSCLC 20, colorectal cancer 48, and prostate cancer 49. This evidence concerns the gene PLK1 and gastric cancer.